Sustained Therapeutic Protein Cocktail Delivery to Prevent Vision Loss After Ocular Trauma
Abstract
The rationale for the proposed studies is that controlled release of anti-inflammatory therapeutics coupled with an injectable, biodegradable drug delivery system will significantly improve visual outcomes after traumatic ocular injury. A novel combination of therapeutics, with evidence of trauma mitigation in other systems, will be investigated for application in ocular models of retinal detachment, proliferative vitreoretinopathy, and traumatic optic neuropathy. The therapeutic cocktail contains haptoglobin, hemopexin, and transferrin, which have potential to reduce inflammation and cell death at the site of injury. The responsive nanoparticle delivery system further has the potential to scavenge stressors and release more therapeutic at injured sites. The objectives of this study are to evaluate the capability of the therapeutic loaded nanoparticles to (1) scavenge high levels of oxidative stressors after trauma, (2) controllably release novel anti-inflammatory therapeutics, and (3) extend therapeutic duration and release. The three aims are: (1) Quantify therapeutic release and efficacy in vitro and in vivo, (2) Determine treatment safety and efficacy in an in vivo model of retinal detachment and proliferative vitreoretinopathy, (3) Determine treatment safety and efficacy in an in vivo model of torsionally induced traumatic optic neuropathy. A new treatment strategy will be developed to provide sustained release of anti-inflammatory therapeutics for vision restoration and/or maintenance after traumatic ocular injury. In the short term, this study will measure how the therapeutic cocktail impacts inflammation and visual outcomes after ocular injury. Identification of a way to prevent complications associated with retinal detachment and optic neuropathy has the potential to significantly improve long-term visual outcomes and quality of life for injured civilians, Warfighters, and Veterans. Localized suppression of inflammation and oxidative stress by the therapeutics and delivery system tested in these studies will demonstrate safety and efficacy sufficient to warrant continued investigation in preclinical and then clinical trials for treating ocular injuries. Any long-term impacts will also translate directly to visual system care in the civilian sector. The proposed research also has the potential to inform treatment strategies for other vision-threatening diseases in which inflammation and oxidative stress are implicated.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Jan 04, 2024
- Source ID
- HT94252310782
Entities
People
- Katelyn Swindle-reilly
Organizations
- Ohio State University
- United States Army